Sanofi (SNY) announced Beyfortus will be broadly available for babies born in Ontario, Quebec, Nunavut, Northwest Territories, and the Yukon ...
This season will be the first time in Ontario that nirsevimab (sold under the brand name Beyfortus) is used to protect babies ...
Sanofi and partner AstraZeneca recently increased production capacity for their RSV antibody shot, sales of which jumped ...
Beyfortus® is the first immunization designed for all infants to help prevent RSV lower respiratory tract disease through their first RSV season. Beyfortus® is also indicated for ...
In the RSV market for infants, AstraZeneca and Sanofi’s Beyfortus leads the way. It achieved sales of 547 million euros ($592 million) in 2023. While cross-trial comparisons carry inherent ...
Sanofi announced that Beyfortus (nirsevimab) will be broadly available for babies born in Ontario, Quebec, Nunavut, Northwest ...
This story first appeared in The Readout newsletter. Sign up for The Readout and receive STAT’s award-winning biotech news delivered straight to your inbox. Good morning! For those who ...
Starting Nov. 4, all babies born in 2024 able to get the Beyfortus immunization for free through their public health unit, ...